INNOFEM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INNOFEM (INNOFEM).
Estrogen receptor agonist; binds to estrogen receptors, leading to transcriptional activation of estrogen-responsive genes, promoting cellular proliferation in target tissues.
| Metabolism | Hepatic metabolism primarily via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone and estriol, conjugated with glucuronide and sulfate. |
| Excretion | Renal (approx. 80% as unchanged drug and metabolites), biliary/fecal (<5%) |
| Half-life | 10-15 hours (terminal) allowing twice-daily dosing; prolonged in hepatic impairment |
| Protein binding | 99% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: 90-100% (immediate-release) |
| Onset of Action | Oral: 30-60 minutes (immediate-release); IV: 5-10 minutes |
| Duration of Action | 6-8 hours (immediate-release) requiring twice-daily administration; sustained-release 12 hours |
2.5 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use caution. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 1.25 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Safety and efficacy not established; no recommended dosing. |
| Geriatric use | No specific dose adjustment; monitor renal function and consider increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INNOFEM (INNOFEM).
| Breastfeeding | Limited data; ferric carboxymaltose is not detected in breast milk after intravenous administration due to high molecular weight and protein binding. M/P ratio unknown. Considered compatible with breastfeeding by most authorities. Monitor infant for gastrointestinal symptoms. |
| Teratogenic Risk | INNOFEM (ferric carboxymaltose) is classified as FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, ferric carboxymaltose caused maternal toxicity and fetal abnormalities at doses 2-3 times the human dose. Risk cannot be ruled out. Use only if potential benefit justifies potential risk to the fetus. Iron deficiency anemia treatment may reduce maternal morbidity. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women; unopposed use should be avoided. Cardiovascular disorders and breast cancer risk are also associated with estrogen therapy.
| Serious Effects |
Undiagnosed abnormal genital bleeding; known or suspected breast cancer; known or suspected estrogen-dependent neoplasia; active thrombophlebitis or thromboembolic disorders; known hypersensitivity to estrogens; pregnancy.
| Precautions | Risk of endometrial hyperplasia and carcinoma; increased risk of thromboembolic events; hypertension; hypertriglyceridemia; gallbladder disease; exacerbation of endometriosis; hypersensitivity reactions. |
Loading safety data…
| Fetal Monitoring | Monitor hemoglobin, hematocrit, ferritin, transferrin saturation before and during therapy. Blood pressure and heart rate monitoring during infusion. Observe for hypersensitivity reactions. Serial fetal ultrasound if used in pregnancy. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment of fertility at therapeutic doses. Correction of iron deficiency may improve fertility outcomes. |